AID Genomics is a research and development-driven diagnostic company focused on the development of precision medicine-based diagnostic solutions primarily for oncology, hereditary rare diseases, and infectious diseases. ‍ One of its primary goals is to enable patients around the world to access more accurate diagnostics and to ensure physicians have the diagnostic tools and data they need to make better therapy recommendations to patients. Its rich research and development division combines cutting-edge technologies such as next-generation sequencing, miRNA, and epigenetics, alongside AI-based analytical tools. The company's strong and diverse partnerships help deliver affordable precision medicine that will improve patients' care and quality of life. ‍ AID Genomics is a member of the AID Private Equity Group.